NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek

Phase III

Drone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose and isotope to a person's cancer. Pan-cancer drugs that fix many tumours, not just one. Miniature particle accelerators.
These are the hopes, dreams and expectations we canvas in our last episode on radiopharmaceutical 'theranostics', the old-now-new cancer technology that is sweeping the globe and capturing imaginations in the world of biotech.
In the final episode of our series NUKED, we speak with Novartis Australia and New Zealand country manager Matt Zeller, Wilsons Advisory equity analyst Dr Melissa Benson, and Cyclotek partnerships and innovation manager Sam Graf about what is happening now to advance this modality into the coming years, and what the distant future might hold.

Support the show

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

บท

1. NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek (00:00:00)

2. Novartis Australia & New Zealand country manager Matt Zeller (00:02:35)

3. Wilson's Advisory equity analyst Dr Melissa Benson (00:12:10)

4. Cyclotek partnerships and innovation manager Sam Graf (00:24:49)